Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum EastWest Bioscience Inc V.EAST.H

Alternate Symbol(s):  HBOSF

Eastwest Bioscience Inc. is a Canada-based vertically integrated wellness company. The Company has a multitude of business units and assets that allow for seed-to-sale supply chain management. The Company sources its raw materials, processes, manufactures, tests, brands, markets and distributes its products to its customers in Canada, the United States, and other countries. The Company owns and... see more

TSXV:EAST.H - Post Discussion

EastWest Bioscience Inc > Q2 Financials
View:
Post by Riskitbiscuit on Apr 08, 2020 7:36pm

Q2 Financials

Positives
  • Management is actively trying to reduce unnecessary costs: decreases in consulting fees, professional fees, travel expenses, share-based payments...etc
  • Overall, expenditures and operating costs are down from previous quarters
  • Profit margins up significantly over previous quarters
Negatives
  • Profitability seems unlikely in near term (Q3 and Q4 2020)
  • Very low on cash, another capital raise seems very likely
  • Sales down overall (despite higher margins)
  • Macroeconomic situation looks bleak 
Comment by OneTwoOneTwo on Apr 09, 2020 8:50am
You mean to say that the only positives are that Rod isn't pocketing as much of the money and leaving the cupboards bare any longer. Or is it that there isn't anything left to take? lol
EastWest Bioscience Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities